Sunrise Diagnostic Laboratories, INC

Sunrise Diagnostic Laboratories, INC was paid $2.38M by Medicaid between Mar 2020 and Nov 2024, across 51 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 57% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in California

Rank by total paid#138 of 561

Median peer was paid$222K

This provider vs. median11×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2020	6,071	$257K
2021	31,295	$837K
2022	22,993	$759K
2023	17,348	$243K
2024incomplete	22,747	$281K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	57%	21,968	13,065	$1.36M
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	14%	20,173	11,577	$328K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	9.8%	3,755	1,714	$234K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	9.2%	14,067	7,887	$218K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	5.5%	4,659	2,068	$132K
84443	Thyroid stimulating hormone (TSH)	<1%	2,753	2,583	$11K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	598	553	$10K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	1,760	1,735	$10K
80053	Comprehensive metabolic panel	<1%	3,272	3,016	$10K
80061	Lipid panel	<1%	2,579	2,474	$8K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	3,440	3,114	$8K
83036	Hemoglobin; glycosylated (A1C)	<1%	2,830	2,658	$7K

39 more codes

G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	<1%	228	$6K
87481		<1%	598	$4K
84153		<1%	1,068	$4K
84481		<1%	545	$2K
82607		<1%	1,163	$2K
99000		<1%	1,832	$2K
86677		<1%	484	$2K
82746		<1%	454	$2K
86038		<1%	479	$2K
82728		<1%	450	$2K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	<1%	31	$2K
80164		<1%	395	$2K
84439		<1%	773	$1K
81002		<1%	2,173	$1K
83550		<1%	448	$938.79
84550		<1%	1,250	$874.55
83540		<1%	495	$871.31
82043		<1%	742	$813.08
86063		<1%	453	$708.25
86430		<1%	453	$703.16
86140		<1%	493	$689.67
87631		<1%	32	$598.81
36415	Collection of venous blood by venipuncture	<1%	806	$420.70
83001		<1%	242	$401.13
85651		<1%	506	$370.65
82670		<1%	253	$342.02
86689		<1%	14	$333.48
87653		<1%	255	$331.36
84479		<1%	181	$284.80
84144		<1%	220	$252.08
87640		<1%	306	$237.22
83002		<1%	253	$222.10
84402		<1%	124	$164.46
87086	Culture, bacterial; quantitative colony count, urine	<1%	55	$137.18
84146		<1%	228	$124.90
83935		<1%	51	$92.00
86606		<1%	26	$79.63
83735		<1%	25	$41.33
84100		<1%	16	$12.44

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialCUNNINGHAM, ANNA (PRESIDENT / CEO)